VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $66,396,709 | +2.3% | 1,302,407 | +0.2% | 10.86% | +21.6% |
| Q2 2023 | $64,922,000 | +42.4% | 1,300,000 | +6.8% | 8.93% | +51.7% |
| Q1 2023 | $45,605,064 | +35.2% | 1,216,784 | +73.0% | 5.89% | +13.8% |
| Q4 2022 | $33,729,996 | +101.2% | 703,441 | +0.7% | 5.17% | +46.4% |
| Q3 2022 | $16,767,000 | +6.5% | 698,638 | -3.5% | 3.53% | -12.2% |
| Q2 2022 | $15,749,000 | +12.5% | 723,781 | +24.9% | 4.02% | -11.4% |
| Q1 2022 | $13,998,000 | +178.2% | 579,640 | +174.1% | 4.54% | +68.9% |
| Q4 2021 | $5,031,000 | – | 211,483 | – | 2.69% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |